Vol. (20 day Avg.)0
- Biotechnology & Drugs
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.
Glenn SaldanhaExecutive Chairman of the Board, Chief Executive Officer, Managing Director
V. S. ManiGlobal Chief Financial Officer, Executive Director
Harish KuberCompliance Officer, Company Secretary
Cherylann PintoExecutive Director - Corporate Services